Interleukin Genetics Wins International Award for Outstanding Research
Published in the Journal, Nutrition
Paper Reports Value of Specific Nutritional Products is Dependent on
Individual's Genetic Make-up
WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Researchers at
Interleukin Genetics, Inc. (Amex: ILI), today received the 12th John M. Kinney
Award for Nutrition and Metabolism at the annual Congress of the European
Society of Parenteral and Enteral Nutrition, in Florence, Italy. The award
was given for the paper, "Interleukin-1 genotype-selective inhibition of
inflammatory mediators by a botanical: a nutrigenetics proof of concept,"
which was published in Nutrition: The International Journal of Applied and
Basic Nutritional Sciences (2007;23:844-852).
Kenneth Kornman, Ph.D., Chief Scientific Officer at Interleukin Genetics,
and the first author on the publication, commented, "We are honored to receive
the 12th John M. Kinney Award for Nutrition and Metabolism. Many botanical
and nutritional supplements claim to provide countless health benefits without
being subjected to rigorous clinical study. Our paper reports a well-
controlled clinical study has shown the value of specific nutritional products
is dependent on an individual's genetic make-up."
The study, a joint research effort by scientists at Interleukin Genetics
and Nutrilite, a division of Alticor Inc., is one of the few controlled
clinical trials that has shown the value of specific nutritional products is
dependent on an individual's genetic make-up. The data showed that a
proprietary botanical supplement (Nutrilite IL1 Heart Health Supplement) could
lower inflammation in individuals who tested positive for pro-inflammatory IL-
1 gene variations from Interleukin Genetics' Heart Health Genetic Test. These
individuals also had elevated levels of C-reactive protein.
About Interleukin Genetics' Heart Health Genetic Test
Interleukin Genetics' Heart Health Genetic Test was developed to identify
healthy individuals who are genetically predisposed to over-produce
inflammation and are at an increased risk for an early first heart attack.
The Heart Health Genetic Test is marketed on a non-exclusive basis through
Access Business Group International LLC, a division of Alticor Inc.
Interleukin Genetics recently announced an agreement with Access Business
Group International that will permit the expansion of Interleukin Genetics'
distribution network for such genetic tests.
About Nutrilite IL1 Heart Health Supplement
Nutrilite IL1 Heart Health Supplement, a proprietary botanical supplement,
was developed to reduce inflammation in those individuals who are genetic
over-producers. The Nutrilite IL1 Heart Health Supplement is currently
marketed by Quixtar, Inc., a division of Alticor Inc.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized
health company that develops preventive consumer products and genetic tests
for sale to the emerging personalized health market. Focused on the future of
health and medicine, Interleukin Genetics uses its leading genetics research
and scientific capabilities to develop and test innovative preventive and
therapeutic products. Interleukin Genetics currently offers an array of
Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and
Venastat(R) which are sold at the nation's largest food, drug and mass
retailers, and has commercialized genetic tests for periodontal disease risk
assessment, cardiovascular risk assessment, and general nutrition assessment.
Interleukin Genetics is headquartered in Waltham, MA. For more information
about Interleukin Genetics, its products and ongoing programs, please visit
www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements
including statements regarding our ability to develop diagnostic, personalized
nutritional and therapeutic products to prevent or treat diseases of
inflammation and other genetic variations, our ability to screen nutritional
compounds for their effects on inflammatory responses and other genetic
variations, given specific genetic patterns and our ability to make progress
in advancing our core technologies. Because such statements include risks and
uncertainties, actual results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could cause actual
results to differ materially from those expressed or implied by such forward-
looking statements include, but are not limited to, the risk of market
acceptance of our products, the risk of technology and product obsolescence,
delays in product development, the performance of our commercial partners, the
availability of adequate capital, the actions of our competitors and other
competitive risks, and those risks and uncertainties described in our annual
reports on Form 10-K, our quarterly reports on Form 10-Q and other documents
we file with, or furnish to, the Securities and Exchange Commission. We
disclaim any obligation or intention to update these forward-looking
statements.
SOURCE Interleukin Genetics, Inc.
Media, Lisa Rivero, LaVoie Group, +1-978-745-4200 x106,
lrivero@lavoiegroup.com; Investor Relations, Melanie Friedman, Stern Investor
Relations, +1-212-362-1200, melanie@sternir.com
